Chemotherapy – Medical News Asia | Powered by ['mediPr]

More Severe Outcomes in COVID-19 Patients with Cancer

16 May 2022/0 Comments/in COVID-19, Breast Cancer, Haematology, Infectious Disease, Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by Christy Leung

Severe COVID-19 infection does not only bring about patient distress, but also increases public health expenditure in supportive devices such as ventilators. It is necessary to minimise the risk of COVID-19 infection in cancer patients, considering COVID-19 waves are likely to recur regularly and they are the high-risk groups. Personal hygiene measures and COVID-19 vaccination have been demonstrated to be efficacious and should be recommended to cancer patients for lowering the likelihood of hospitalisation, ICU admission and mortality.

ASCO 2021 Liver Cancer Update

11 June 2021/in Gastrointestinal Cancer, Oncology, ASCO 2021 Annual Meeting, Chemotherapy, Immunotherapy, Targeted Therapies/by Coco Chong

The liver cancer trials presented at American Society of Clinical Oncology (ASCO) 2021 were mainly focused on first-line treatments, with a few trials in the neoadjuvant, adjuvant and second-line setting.

the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant-1

The evolving role of NK₁ in CINV management

16 April 2021/in Oncology, Chemotherapy, AE Management/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Lung Cancer Update April 2021

8 April 2021/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Radiology, irAE Management, Targeted Therapies/by Kirsty LEE

With the World Conference on Lung Cancer (WCLC) 2020 completed last January, several new and clinical relevant phase 2 and phase 3 studies on Lung Cancer have been published. We summarised some key data for you.

Abemaciclib: A review of the evidence through clinical cases

25 March 2021/in Breast Cancer, Oncology, Chemotherapy, Endocrine Therapy, Radiology, Targeted Therapies/by Kirsty LEE

There is no excerpt because this is a protected post.

Breast cancer update January 2021

1 February 2021/in Breast Cancer, Oncology, Chemotherapy, Endocrine Therapy, Radiology, Targeted Therapies, Translational Research/by Kirsty LEE

With the San Antonio Breast Cancer Conference (SABCS) 2020 by AACR just completed, several new and clinical relevant phase 2 and phase 3 have been published in the Journal of the American Medical Association, Clinical Cancer Research, New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. [‘mediPr] provides you with an overview.

Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

7 September 2020/0 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Chemotherapy, Targeted Therapies/by Kirsty LEE

Aberrant RET activation has shown to be a clinical driver of tumour growth and proliferation. It is reported that 1-2% of non-small cell lung cancer patients have activating RET fusions. Clinical characteristics of these patients are generally younger (<60 years) with minimal or no smoking history, and frequent presentation with brain metastases at diagnosis of advanced disease. RET mutations are mutually exclusive with other common lung cancer genetic abberations, such as reported for KRAS, EGFR, and ALK.

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

10 July 2020/0 Comments/in Gastrointestinal Cancer, AIDS, HIV, Infectious Disease, Oncology, Chemotherapy/by Kirsty LEE

The incidence of anal cancer has been increasing over the past decade, but currently still constitutes 0.5% of all cancer diagnoses in the United States. When the cancer has metastasised, prognosis remains poor, with relative 5-year survival rates of approximately 30%. The current standard of care for metastatic anal cancer is cisplatin-based chemotherapy combined with 5-fluorouracil (5-FU). However, no randomised clinical trial investigating the optimal chemotherapy regimen for this disease has been conducted. The InterAAct trial was launched to investigate cisplatin plus FU against carboplatin plus paclitaxel in advanced anal cancers, and full results were recently published in the Journal of Clinical Oncology.

ASCO-2020-ASCO20-virtual-meeting-NSCLC-SCLC-lung-cancer-breast-cancer-hepatocellular-cancer-HCC-colorectal-cancer-CRC-e1593749874717

ASCO 2020 Lung, Breast, and Liver Cancer Update

30 June 2020/0 Comments/in China, Breast Cancer, Gastrointestinal Cancer, Conferences, Lung Cancer, Oncology, ASCO 2020 Annual Meeting, Chemotherapy, Endocrine Therapy, Immunotherapy, Targeted Therapies/by Kirsty LEE

This year, ASCO 2020 was held as a virtual conference due to the COVID-19 pandemic. This is a summary of key trials presented at ASCO, focusing primarily on breast cancer, liver cancer, and lung cancer.

gastric-adenocarcinoma-ramucirumab-cyramza-pembrolizumab-nivolumab-trastuzumab-dmmr-msi-her2-vegf-vegfr-gastric-cancer-gej-gastroesophageal-junction-cancer-pd-1-pd-l1-eli-lilly-lilly

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

30 April 2020/Enter your password to view comments./in Gastrointestinal Cancer, Oncology, Chemotherapy, Immunotherapy, Surgery, Targeted Therapies, Pathology/by 陳穎樂醫生

There is no excerpt because this is a protected post.